Lemzoparlimab

Summary

Lemzoparlimab (CHEMBL4650520) is a phase-3 clinical-stage antibody; indicated across 5 conditions including myelodysplastic syndrome and acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 5 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650520
Name	Lemzoparlimab
Type	Antibody
Max phase	3

Also known as: Lemzoparlimab, TJ-011133, Tj011133, TJ011133, LEMZOPARLIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
myelodysplastic syndrome	3	MONDO:0018881	EFO:0000198
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
lymphoma	1	MONDO:0005062	EFO:0000574
plasma cell myeloma	1	MONDO:0009693	EFO:0001378
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05709093	PHASE3	TERMINATED	A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
NCT04202003	PHASE1/PHASE2	COMPLETED	A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT03934814	PHASE1	COMPLETED	Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
NCT04895410	PHASE1	TERMINATED	Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
NCT04912063	PHASE1	TERMINATED	Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).